Login / Signup

Risk stratification biomarkers for Staphylococcus aureus bacteraemia.

Yi CaoAlessander O GuimaraesMelicent C PeckOleg MaybaFelicia RuffinKyu HongMontserrat Carrasco-TrigueroVance G FowlerStacey A MaskarinecAdrienne G Randolph
Published in: Clinical & translational immunology (2020)
These biomarkers offer potential utility to identify patients at risk of persistent bacteraemia to guide diagnostic imaging and clinical management. Low biomarker levels could be used to rule out the need for more invasive TEE imaging in patients at lower risk of infective endocarditis. These biomarkers could enable clinical trials by enriching for patients with the greatest need for novel therapies.
Keyphrases
  • staphylococcus aureus
  • clinical trial
  • high resolution
  • randomized controlled trial
  • biofilm formation
  • pseudomonas aeruginosa
  • open label
  • phase ii
  • climate change